Skip to content
Screener

Net Change in Cash at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
-$2.2B-1,432%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$49M-198%
RFL
Rafael Holdings, Inc.RFL
-$7.28M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
-$16.17M-47.5%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$120.3M+65.2%
XER
Xeris Biopharma Holdings, Inc.XERS
$10M+1,083%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$681.73M+6.6%
Enterprise value$537.9M-17.8%
P/E11.7×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemSix months ended June 30, 2026Six months ended June 30, 2025
Payments of principal on insurance financing arrangements(372)
Net cash (used in) provided by financing activities(51,219)2,988
Effect of exchange rate changes on cash and cash equivalents(109)286
Net increase in cash and cash equivalents82,91513,927
Cash and cash equivalents, beginning of period62,40633,785
Cash and cash equivalents, end of period$145,321$47,712
Supplemental cash flow information:
Cash paid for interest$1,370$2,626

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s net change in cash?
Zevra Therapeutics, Inc. (ZVRA) reported net change in cash of $49.73M in Q2 2026.
How has Zevra Therapeutics, Inc.'s net change in cash changed year-over-year?
Zevra Therapeutics, Inc.'s net change in cash increased by 379.4% year-over-year, from $10.37M to $49.73M.
What is the long-term trend for Zevra Therapeutics, Inc.'s net change in cash?
Over 3 years (2022 to 2025), Zevra Therapeutics, Inc.'s net change in cash has grown at a -15.2% compound annual growth rate (CAGR), from -$46.88M to $28.62M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Zevra Therapeutics, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude